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ringer) on days 1, 3, 5, 7, 9,11,13,15,22 and 29, and at months 12,13,14,15,
16,17,18, and 24, respectively.
Results: Seroprotective antibody levels (> 1=20 mlU) were reached in
30% of subjects on day 11, in 81% on day 13, in 96.3% on day 15 and in
100% on day 22. GMTsforboth genders combined were 14,31, 100 and 242
mlUImI respectively. Female subjects reached seroprotection faster than
males, i.e. 93% vs 69% at day 13. As expected, GMTs were higher for
females, i.e. 36 vs27 mlU/ml on day 12 and 126 vs n mlU/mI on day 15. At
month 12 GMTs (both genders) were still high with 161 mlU/mI and
reached a peak of3n6 mlUIml after booster vaccination. At month 24 high
levels of 1175 rnJUIml persisted. Vaccination was well tolerated.
Conclusions: The aluminium-free, virosome formulated hepatitis A vaccine
is highly immunogenic. After a single dose protective levels of anti-HAV
antibodies develop in single individuals from day 9 onwards and by day 15
over 90% of individuals arc protected.
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IWe091 Quantitative analysis of human cytomegalovirus DNA
in longitudinal samples of BAL fluid from lung transplant
recipients
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Objectives: Cytomegalovirus (CMV)-infection is a common cause of
mortality and morbidity in transplant patients. In some sample material,
qualitative tests for CMV DNA may be too sensitive to discriminate
between patients with and without CMV disease. We investigated whether
a longitudinal quantification of CMV DNA in bronchoalveolar lavage
(BAL) fluid could be used to determine a viral load associated with disease in
lung transplant recipients.
Methods: CMV DNA levels in 340 BAL samples from 35 consecutive
lungtransplanted patients were analysed by the Vitral Quant Quantitative
CMV Detection Kit (BioSource Europe) during a median of 18 months.
Seventeen of the patients developed 27 episodes ofCMV disease.
Results: Patients with CMV disease had a significantly higher mean level of
CMV copies/mL BAL (1120 ± 4379) fluid compared to those without (180
± un, p < 0.01). Viral load as well as acute rejection were independent
risk factors associated with CMV disease, whereas HLA-DR matching and
bask immunosuppressive therapy were not. A diagnostic definition of
normality based upon the mean level of all the episodes without CMV
disease + 2 SD would discriminate only 9 of the 27 CMV episodes.
Conclusions: Although the viral load is increased during episodes ofclinical
CMV disease in lung transplant recipients, the quantitative PCR assessment
ofCMV DNA in BAL fluid is not specific enough as a diagnostic tool for
CMV disease. Other sample materials such as serum are currently investi-
gated quantitatively.
IWe010 IOKT3 treatment and lymphoma are possibly related
to the presence but not the amount of Epstein-Barr virus
genomes in serum in liver transplant recipients
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ItutitutefoT Infectious Disease Control, Karo/inska Institutet, Stockholm,
Sweden
Objectives: To compare immunogenicity and safety of the subcutaneous
(s.c.) versus the intramuscular (i.m.) administration of an aluminium-free,
virosome formulated hepatitis A vaccine (500 RIA units) in healthy adult
volunteers.
Methods: In an open, uncontrolled gender stratified study 113 adults, aged
18-45 years, were enrolled. 44 seronegative volunteers (Group A: 23 f, 21 m)
received 0.5 ml ofhepatitis A vaccine s.c. and a control group of69 adults (B:
33 f, 36 m) i.m. on day 1 and at month 12. Safety was assessed for 4 days after
the immunisations. Serum anti-HAV antibodies were determined by EtA
(ENZYMUN Boehringer) at baseline, on day 29, and at months 6,12 and
13.
Results: Seroprotective antibody levels of > 1=20 mlUIrnJ were attained
on day 29 by 95.5% and 95.6'Yo, at month 6 by 91 % and 90%, and at month
12 by 93% and %% ofsubjeers in groups A and B, respectively. GMTs were
lower for Group A at all time points, but still 68 mlUIml vs 89 mlUIrnJ at
month 12. Strong booster responses were recorded for groups A (938 mlUI
ml or 14-fold rise) and B (2368 rnJU/ml or 27-fold rise). GMTs for female
subjects were generally higher, except for the booster response in group A
(877 vs 1014 mIU/rnJ). Vaccination was well tolerated.
Conclusions: With the aluminium-fn:e, virosome formulated hepatitis A
vaccine the s.c. administration can be chosen depending on the need of the
subject to be vaccinated without the risk ofsubcutaneous nodules. Seropro-
tective titers are reached within 1 month for both routes and are still present
in > 90% at month 12.
Objective: We sought to determine factors affecting the Epstein-Barr virus
(EBV) genome load in serum after liver transplantation (LTX).
Material & Methods: Real-time PCR on serum was used after extraction
ofDNA by Qaigen for measurement ofthe EBV genome load. Consecutive
serum samples obtained from 21 LTX patients preLTX and within the 6nt
year were examined. Steroid resistant acute rejections were treated with
OKT3 in 4/11 cyclosporin A (CsA) and 3/10 tacrolimus treated patients.
Results: EBV DNA was found in 5111 CsA and 6/10 tacrolimus treated
patients. It was demonstrated in 6 of7 patients with OKT3 therapy (3 CsA
and 3 tacrolimus cases). There was no difference in median EBV DNA copy
number in patients with CsA or tacrolimus (310/ml vs. 380/rnJ), or with or
without OKT3 treatment (380/ml vs. 370/ml). EBV genomes were not
found at the end ofacyclovir or ganciclovir therapy but was detected 1 to 14
weeks later in 4 of 6 cases. One patient developed EBV lymphoma and
another one EBV hepatitis 13 months and 24 days postLTX, respectively.
Both patienrs had received OKT3. EBV genome was found in their serum
samples. but the load was not significantly different from what was found in
other patients.
Conclusion: EBV in serum is a possible marker of an active infection.
OKT3-treatment seems to be of greatest importance for its appearance.
EBV DNA in serum might be a marker for EBV lymphoma, but in this
srudy viral load was not different in patients with lymphoma as compared
with other patients.
IWe011! Candida glabrata fungemia in immunocornpromised
cancer patients: Epidemiology and outcome analysis
M. Mardani, H. Hanna,]. Abbas, A. Alrahwan, R. Hachem, I. Raad
Univ. of Texas M. D. Anderson Cancer Center, Houston, TX, United States
Between January 1993 and May 1998, we identified % immunocompro-
rnised cancer patients (pts) with Candida glabrata fungemia. With the wide-
spread use offluconazole prophylaxis after 1992 at our center, the incidence
of C. glabrata fungemia increased. Most immunocompromised cancer pts
"';th C. glabrata fungemia were neutropenic (47%). The underlying disease
was leukemia (47%), solid tumor (38%), and lymphoma (15%). Most (64%)
of these pts with C. glabrata fungemia received fluconazole prophylaxis prior
to the onset of fungemia. Disseminated infection occurred in 37 pts (39%),
while 15% of all C. glabrata fungemia infections were catheter-related.
Breakthrough candidemia on amphotencin B or liposomal compound
regimen occurred in 10 pts, 5 of whom had disseminated infection. C.
glabrata fungemia was the primary cause ofdeath in 13 pts (14%), and was a
contributing factor to death in 29 other prs (39%). In conclusion, C.glabrata
fungernia in immunocompromised cancer pts is associated with high
frequency of dissemination and mortality. This infection should be con-
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sidered in any febrile, neutropenic immunocompromised cancer pt receiv-
ing fluconazole.
1WeO121 Scedosporium infection after lung transplantation
M. Tamm, M. Malouf, A. Glanville
Lung Trallsplant Unit, St. Vincent's Hospital, Sydney, Australia
Scedosporium apiospermium and ScedosporiuIII prolificans infections have mainly
been described after bone marrow transplantion and only occasionally in
solid organ transplant recipients. One lethal case of disseminated Scedospor-
ium prolificans infection was reported in a single lung transplant recipient. We
analysed the clinical course, outcome and risk factors of 7 lung transplant
recipients who developed pulmonary infection with scedosporium. Early
pu1rnonary complications included airway stenosis (I), empyema (I), rejec-
tion (5), CMV pneumonitis (5), bacterial- (7) and aspergillus (4) infection.
Scedosporium apiospermium was documented in bronchoalveolar lavage
(BAL) of all 7 and Scedosporium prolificans in 3 patients 11 to 58 months
after transplantation. Infiltrates on chest X-ray were uncommon. 4 patients
had been treated with itraconazole for several months because ofaspergillus
detection in BAL. All 7 patients showed airway problems (1 ischaemic
airway stenosis; 6 bronchiolitis obliterans). Treatment with itraconazole/
fluconazole was not able to erradicate scedosporium in 5 of7 cases. 3 of the 7
patients are alive and 4 died with advanced bronchiolitis obliterans months
or years after detection of scedosporium.
Conclusion: pulmonary scedosporium infection was seen in lung transplant
recipients with structurally abnormal airways. Erradication proved difficult
but under treatment with itraconazole and fluconazole this opponunistic
infection did not disseminate.
[WeO131 Prospective study comparing the Talcott and the
MASCC dlnlcal prediction rules for the identification of low-risk
(LR) patients (PTS) with febrile neutropenia (FN)
]. P. Chami, M. Paesmans, L. Dubreucq, F. Crokaen, M. Aoun,].
Klastersky
Illstitut Jules Bordet, Universite Lib,e de Bruxelles, Brussels. Belgium
Purpose: The study was undertaken to compare the performances of the
Talcott and the MACC clinical prediction rules for the identification ofFN
pts at low risk of serious medical complication development.
Patients and Methods: All FN episodes occurring at our institution
bcnvecn NovclU.bcr 97 and April 99, were pro§:pcctively foUo'\N'cd. At the
onset of fever, outpatients with controlled cancer and without any serious
comorbidity were predicted at LR by Talcott et al. (group IV). Outpatients
with age less than 60 y, a mild or moderate burden of illness, absence of
hypotension, of dehydration and ofchronic obstructive pulmonary disease
(COPD), diagnosis ofsolid tumor (ST) or hematologic malignancies (HM)
without previous fungal infection; were selected as LR by the MASCC
clinical prediction role (score ~ 21).
Results: 92 pts were included, 42/50 with HM/ST. Overall, favorable
outcome occurred in 79 pts (86%). 10 14 and 73 pts respectively predicted
at LR by Talcott's and MASCC, favorable outcome occurred in 13 (93%)
and 67 pts (92%). According to these results, sensitivity in identifying pts at
LR, is markcdly lower with the Talcott's model (16%) than the MASCC
scoring system (85%). No mortality occurred in the Talcott group IV. while
two pts, predicted at LR by the MASCC score, died from infection.
Conclusion: These two risk-assessment models accurately stratified the
medical risk of FN pts using only clinical information available on the
first day of their course. Moreover, the ability of idelllifying pts at LR has
been improved by the MASCC scoring system. Low risk pts are on
appropriate population in which to study less intensive treatment strategies.
[We0141 Autopsy findings in patients with heart
transplantation
M. Gurgui. C. Rodriguez, N. Rabella,]. L. Barrio, R. Arguelles, M.
Puig, P. Domingo
Hospital de Sarli Pau. Universitat Autanoma de Barcelona. Spai"
Objectives: To determine the frequency of infection and rejection as the
cause ofdeath after heart transplantation (HT) and to correlate these findings
with antemortem diagnosis
Methods: From May 1984 to December 1997, 232 HT were performed in
our hospital. We reviewed autopsy findings of 60 patients who died after
HT.
Results: Twenty-three patients (38%) died as a result ofan infection that in 8
cases was associated to rejection and 11 (18%) had acute rejection. In 26
patients (44%) death was due to other causes.
Infections were bacterial in 11 patients (48%), fungal in 5 (22%), due to
CMV in 3 (13%), and to T. gondii in 1 (4%). Three patients (13%) had
polymicrobial infections (anaerobes + CMV; C. a/bieans + S.faeealis; P.
carinii + CMV + C. a/bicans). Infections affected mainly the lungs (16) and
myocardium (5). Eleven patients had septicaemia and 4 patients had a
disseminated infection. In 8 patients infections were diagnosed post-
monem (3 fungal infections, 3 by CMV, a tuberculosis and a disseminated
toxoplasmosis).
Conduslons: 1) Infections from a pre-mortem non diagnosed etiology,
were a frequent fUlding (35%) on autopsies ofHT patients. 2) Fungus and
virus were the most frequent etiologic agents. 3) Infections were dissemi-
nated and often affected unexpected organs.
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1WeP30S! A fatal Legionella longbeachae pneumonia in an
alla-BMT patient
H. Rodriguezl , PH. Martiat1, P. Grenier!, D. Daneau\ T. Berghmansl ,
Y. De Gheldre2, F. Crokaertl , M. Aoun!
'I"stitutJules Bordet; 2H. Erasme. Brussels. Belgium
Case report: A 39 year old man with CML was admitted one year post allo-
BMT for treatment ofCMV infection. He was receiving at home corticos-
teroids because of GVHD. On admission the physical examination was
unremarkable and treatment with ganciclovir and immunoglobulines was
started. On day 5 the patient became febrile with cough, white expectora-
tion and left chest pain. CT Scan showed left basal infiltrate and ceftazidime.
c1arithromycin and Ambisome® wete added. On day 7 small intraeelIular
gram-negative bacilli were shown in the BAL direct exam. 10spite ofshifting
to erythromycin and piperacillin-tazobactam, progressive majoration ofthe
previous lesions on chest CT scan led to ICU admission. A second BAL
showed again intracellular gram-negative bacil1i and in the culture Legiomlla
longbeaehae was isolated. Antibiotics were changed again because persistenr
degradation to c1arithromycin. ciprofloxacin plus rifampicin but only a
transient improvement was obtained and he died on day 32 because of
massive alveolar haemorrhage.
Discussion: What wa~ the ~l1rce ofthi~ infection: Community or nOMK:O-
mial acquisition? The patient mentioned showering at the hospital since his
admission but also, gardening work at home shortly before admission. Two
systematic investigations for Legionella detection in hospital water were
negative. What were the problems in the diagnosis? Two BALs were
necessary for isolation of the Legionella and a molecular method for
identification was required. Conventional Legionella serology was negative.
Why the patient didn't respond to the adequate and early treatment?
Although Erythromycin and more recently quinolone/macrolide combina-
tions are the preferred therapy in irnmunocomprornised patients, therapeu-
tic failures without emergence of resistance against commonly used
antimicrobial agents were described.
IWeP3091 Successful treatment of leuconostoc species
bacteremia in recipients of bone marrow transplantation (BMT)
by daptomycin (D)
S. Tozzi, Y. Golan, S. Hadley, D. D. Poutsiaka, D. R. Snydman
New Engla"d Medical Cerller, Boston. Massachusetts, United States
Leuconostoc species are rare gram-positive pathogens which may infect
immunocompromised hosts and cause bacteremia. Leuconostoc species are
vancomycin-resistant due to the presence of an alanine-lactate depsipeptide
at the terminus oftheir cell wall precursors which does not provide a binding
site for vancomycin. Daptomycin is a lipopeptide antibiotic that inhibits
Iipoteichoic acid synthesis and is undergoing investigational use for the
treatment of infections with gram-positive bacteria, including those resistant
to vancomycin.
We used D to treat Leuconostoc bacteremia in two BMT patients. Each
developed neutropenia and fevers and received initial empiric therapy that
included vancomycin. Lel/conostoc species were isolated from multiple blood
